Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

作者
James Chih‐Hsin Yang,Suzanne Louise Topalian,D Parkinson,Douglas J. Schwartzentruber,Jeffrey S. Weber,Stephen E. Ettinghausen,D E White,Seth M. Steinberg,David J. Cole,H I Kim
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:12 (8): 1572-1576 被引量:169
标识
DOI:10.1200/jco.1994.12.8.1572
摘要

PURPOSE: A randomized prospective study was performed to compare the efficacy and toxicity of high-dose intravenous bolus interleukin-2 (IL-2) and a lower-dose intravenous bolus regimen for the treatment of metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Between March 1991 and April 1993, 125 patients with metastatic RCC were randomized to receive IL-2 by intravenous bolus every 8 hours at either 720,000 IU/kg (high-dose) or 72,000 IU/kg (low-dose) to the maximum-tolerated number of doses (or a maximum of 15 doses). After approximately 7 to 10 days, both treatment groups were re-treated with a second identical cycle of therapy. Those patients who were stable or responding to treatment 5 to 6 weeks later went on to receive re-treatment with another course (two cycles) of therapy. Response rates and toxicity were determined for the two treatment arms. RESULTS: One hundred twenty-five patients received a total of 208 courses of therapy. Sixty patients were randomized to receive low-dose, and 65 to receive high-dose IL-2. There were no treatment-related deaths in either arm. There was a greater incidence of grade III or IV thrombocytopenia, malaise, and hypotension in patients who received high-dose IL-2, while patients who received low-dose IL-2 had significantly more infections. Three percent of treatment courses with low-dose IL-2 required vasopressor support, compared with 52% of courses with high-dose IL-2. Patients who received low-dose IL-2 had a 7% complete response (CR) and an 8% partial response (PR) rate, and patients who received high-dose IL-2 had a 3% CR and a 17% PR rate. CONCLUSION: Low-dose intravenous bolus IL-2 represents an effective regimen for the treatment of metastatic RCC, with preliminary results comparable to those observed with high-dose IL-2. Low-dose IL-2 can be administered with significantly fewer complications, reduced use of vasopressor support, and fewer admissions to an intensive care unit (ICU).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ的应助被刀疤尤金采纳,获得30
刚刚
刚刚
1秒前
什么虾仁蛋挞完成签到,获得积分10
1秒前
Anoxia完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
马少兴发布了新的文献求助10
2秒前
2秒前
zhaodan完成签到,获得积分10
2秒前
英俊的铭的应助被JueR采纳,获得10
2秒前
3秒前
年轻幻柏发布了新的文献求助10
3秒前
从容盼旋发布了新的文献求助30
4秒前
Anoxia发布了新的文献求助10
4秒前
aa的应助被科研通管家采纳,获得10
4秒前
林小昀发布了新的文献求助10
4秒前
领导范儿的应助被科研通管家采纳,获得10
4秒前
我是老大的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
null的应助被科研通管家采纳,获得10
5秒前
小巧妙梦发布了新的文献求助10
5秒前
彭于晏的应助被科研通管家采纳,获得10
5秒前
秋风的应助被科研通管家采纳,获得10
5秒前
null的应助被科研通管家采纳,获得10
5秒前
顾矜的应助被科研通管家采纳,获得10
5秒前
Hello的应助被科研通管家采纳,获得10
6秒前
半夏生姜完成签到,获得积分10
6秒前
AN的应助被科研通管家采纳,获得30
6秒前
apricity199的应助被科研通管家采纳,获得10
6秒前
6秒前
秋风的应助被科研通管家采纳,获得10
6秒前
6秒前
6秒前
望月QAQ发布了新的文献求助10
6秒前
酷酷慕蕊完成签到,获得积分10
7秒前
水月发布了新的文献求助10
7秒前
小狒狒完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741